Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Abbott Laboratories : Correction to Rapid Covid-19 Tests Article (Sept. 8)

share with twitter share with LinkedIn share with facebook
09/09/2020 | 01:48pm EDT

Governors from 10 states have partnered with the Rockefeller Foundation to acquire millions of antigen tests. "Public Health Officials Pursue Covid-19 Tests That Trade Precision for Speed" at 7 a.m. ET on Sept. 8, incorrectly said that more than two dozen states, cities and tribes had entered into the partnership.

 


Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 1.12% 109 Delayed Quote.25.49%
ORASURE TECHNOLOGIES, INC. 6.77% 15.92 Delayed Quote.98.26%
share with twitter share with LinkedIn share with facebook
All news about ABBOTT LABORATORIES
10/23GLOBAL MARKETS LIVE : Intel, Mattel, Nordea…
10/22Quest raises profit forecast as COVID-19 tests demand to jump
RE
10/22ABBOTT LABORATORIES : Reports third-quarter 2020 results, achieves strong double..
AQ
10/21ABBOTT LABORATORIES : Raises 2020 Earnings Guidance
DJ
10/21ABBOTT LABORATORIES : 3Q Profit, Sales Rise on Covid-19 Testing
DJ
10/21Abbott says COVID-19 test demand to grow in 2021
RE
10/21ABBOTT : 3Q Earnings Snapshot
AQ
10/21ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
AQ
10/21Abbott quarterly profit rises 28.3% on strong sales of COVID-19 tests
RE
10/21ABBOTT : Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnin..
PR
More news
Financials (USD)
Sales 2020 33 885 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 438 M - -
P/E ratio 2020 44,5x
Yield 2020 1,33%
Capitalization 193 B 193 B -
EV / Sales 2020 6,03x
EV / Sales 2021 5,27x
Nbr of Employees 107 000
Free-Float 88,8%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 117,78 $
Last Close Price 109,00 $
Spread / Highest target 19,3%
Spread / Average Target 8,05%
Spread / Lowest Target -24,8%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES24.10%190 845
MEDTRONIC PLC-1.79%149 794
BECTON, DICKINSON AND COMPANY-11.65%69 650
HOYA CORPORATION12.78%42 617
BAXTER INTERNATIONAL INC.-3.03%41 050
DEXCOM, INC.87.89%39 350